Sonoma Biotherapeutics

Since biotech valuations on public markets peaked in September 2021, the sector has had to contend with reduced financing availability and harsher conditions for deal-making. In December 2023, Scrip

Who: Regeneron Pharmaceuticals, Inc. and Decibel Therapeutics What: Regeneron will acquire Decibel Therapeutics, its partner on the development of gene therapies for hearing loss since 2017. Why:

AstraZeneca is to work with Quell Therapeutics to develop its Treg cell therapies in two autoimmune disease areas, paying out $85m upfront in a deal which could be worth well over $2bn. The UK pharma

Dualyx is heading towards the clinic with its regulatory T cells (Tregs) candidates, armed with €40m and the backing of several top-tier healthcare investors. The Belgian group's series A fundraising